Investigative Ophthalmology & Visual Science Cover Image for Volume 59, Issue 9
July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Risk of recurrent and chronic disease in a large cohort of acute central serous chorioretinopathy with long-term follow-up
Author Affiliations & Notes
  • Danial Mohabati
    Leiden University Medical Center, Leiden, Netherlands
    Rotterdam Ophthalmic Institute, Rotterdam, Netherlands
  • Tom O A R Missotten
    Rotterdam Eye Hospital, Rotterdam, Netherlands
  • Eiko de Jong
    Department of Ophthalmology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, Netherlands
  • Camiel Boon
    Leiden University Medical Center, Leiden, Netherlands
    Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
  • Suzanne Yzer
    Rotterdam Eye Hospital, Rotterdam, Netherlands
  • Footnotes
    Commercial Relationships   Danial Mohabati, None; Tom Missotten, None; Eiko de Jong, None; Camiel Boon, None; Suzanne Yzer, None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 6075. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Danial Mohabati, Tom O A R Missotten, Eiko de Jong, Camiel Boon, Suzanne Yzer; Risk of recurrent and chronic disease in a large cohort of acute central serous chorioretinopathy with long-term follow-up. Invest. Ophthalmol. Vis. Sci. 2018;59(9):6075.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To study typical acute cases of central serous chorioretinopathy (aCSC), and evaluate the risk of transition to a recurrent and chronic CSC phenotype, based on multimodal imaging.

Methods : The medical records and multimodal imaging at presentation were reviewed in patients diagnosed with CSC. Only typical aCSC patients were included showing serous subretinal fluid (SRF), one focal leakage spot on fluorescein angiography (FA), and retinal pigment epithelium (RPE) alterations limited to less than one optic disc diameter in size in the affected eye. All patients had to show complete recovery from the first CSC episode. Recurrence of CSC and disease progression were retrospectively investigated through multimodal imaging during follow-up. Increase in RPE alterations in the affected and unaffected eyes were accepted as signs of chronicity.

Results : 295 affected eyes of 291patients (75% male, mean age 43 years) were included. Mean Snellen visual acuity at diagnosis was 20/25. 153 eyes (52%) had a spontaneous resolution, while 142 eyes (48%) recovered after early treatment (mean: 1, range: 1-3 treatments) of their first episode. In 83 eyes one or more recurrence of SRF was reported (mean follow-up: 26 months). In a subgroup including 197 affected eyes (67%) with more than one year of follow-up (mean: 37, range: 12-247 months), 73 eyes (37%) experienced on average 1.4 CSC recurrences (range: 1-6 recurrences). On follow-up FA (30 months after baseline FA), 22 eyes (11%) showed an increase in cumulative RPE alterations over time, and RPE alterations were observed in 28 fellow eyes (14%) in this subgroup. Mean Snellen visual acuity in this subgroup, as well as the whole aCSC group was equal to 20/20 at final visit.

Conclusions : Based on clinical findings on multimodal imaging, most typical aCSC patients showed a spontaneous recovery of their first disease episode. In our study, one-third of aCSC patients showed a recurrent disease character, while only a small minority with documented long-term follow-up showed a more chronic process. The mean final visual outcome was good in the whole aCSC group.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×